---
title: "辉瑞股票的深度下跌引发了关于其长期价值的争论"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/288182651.md"
description: "辉瑞的股票自 2021 年高峰以来已下跌超过 50%，原因是专利到期和 COVID 产品销售下降。分析师的情绪分歧，大多数人持谨慎态度，而一些人则将此次下跌视为逆势买入的机会。该公司继续推进其在疫苗、肿瘤学和偏头痛治疗方面的研发管线，并在终止内部项目后收购了一项 GLP-1 候选药物"
datetime: "2026-05-31T21:01:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288182651.md)
  - [en](https://longbridge.com/en/news/288182651.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288182651.md)
---

# 辉瑞股票的深度下跌引发了关于其长期价值的争论

Stock under pressure: Pfizer shares are down over 50% from 2021 highs, weighed by patent risks and COVID product declines. Investor sentiment split: Most analysts rate the stock cautiously, but some see the sell-off as a contrarian buying opportunity. Pipeline in focus: Pfizer is advancing vaccines, oncology, and migraine drugs, and acquired a GLP-1 candidate after ending its own program.

### 相关股票

- [PFE.US](https://longbridge.com/zh-CN/quote/PFE.US.md)
- [BBH.US](https://longbridge.com/zh-CN/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/zh-CN/quote/PBE.US.md)
- [FBT.US](https://longbridge.com/zh-CN/quote/FBT.US.md)
- [IHE.US](https://longbridge.com/zh-CN/quote/IHE.US.md)
- [LABU.US](https://longbridge.com/zh-CN/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/zh-CN/quote/IBB.US.md)
- [VHT.US](https://longbridge.com/zh-CN/quote/VHT.US.md)
- [BIB.US](https://longbridge.com/zh-CN/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/zh-CN/quote/XBI.US.md)
- [IBBQ.US](https://longbridge.com/zh-CN/quote/IBBQ.US.md)
- [LABD.US](https://longbridge.com/zh-CN/quote/LABD.US.md)
- [SBIO.US](https://longbridge.com/zh-CN/quote/SBIO.US.md)
- [IXJ.US](https://longbridge.com/zh-CN/quote/IXJ.US.md)
- [ARKG.US](https://longbridge.com/zh-CN/quote/ARKG.US.md)
- [XLV.US](https://longbridge.com/zh-CN/quote/XLV.US.md)

## 相关资讯与研究

- [FDA 准辉瑞公司一款用于治疗儿童出血性疾病的药物](https://longbridge.com/zh-CN/news/289106966.md)
- [规避科技股剧烈波动，精选 8 只稳健标的个股](https://longbridge.com/zh-CN/news/289277399.md)
- [Cerity Partners LLC 购买了辉瑞公司 1,448,806 股股票](https://longbridge.com/zh-CN/news/289292675.md)
- [辉瑞的 Hympavzi 获得 FDA 批准扩展适应症，用于治疗血友病](https://longbridge.com/zh-CN/news/289169446.md)
- [辉瑞表示，美国食品药品监督管理局（FDA）已批准扩大 HYMPAVZI 用于治疗血友病 A 和 B 的适应症](https://longbridge.com/zh-CN/news/289046752.md)